News

Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
The Economist2d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
NBC New York3d
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than ... trial results for its next-generation obesity drug candidate CagriSema. Novo's key U.S. rival Eli Lilly on Thursday reported an expectation ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...